![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 19, 2025
Blood and breast cancer research highlights from the 67th American Society of Hematology Annual Meeting and Exposition, and the San Antonio Breast Cancer Symposium
November 21, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
July 10, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
June 11, 2025
The changes broaden eligibility and clarify treatment planning details in this phase 2 trial testing daratumumab-hyaluronidase to eliminate minimal residual disease after initial chemotherapy
August 14, 2024
Thoughts on the evolving clinical cancer research environment—and practice-changing results in acute lymphoblastic leukemia
October 19, 2023
These four leukemia treatment trials and an observational study of myelodysplastic syndromes are all open and enrolling patients
February 10, 2023
The phase 3 E1910 clinical trial provides strong evidence for adding immunotherapy to standard front-line consolidation chemotherapy
December 20, 2022
This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population
October 13, 2022
This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
June 21, 2022
This single-arm phase 2 study aims to rid patients of residual disease following initial treatment
September 30, 2021
This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL